You are not logged in
You need to be a member to print this page.
Sign up for free membership, or log in.
Find out more about our membership benefits
Authors:
BJCardio editorial team
An abundance of new information on the controversy surrounding drug-eluting stents was presented and discussed at the Transcatheter and Therapeutics (TCT) meeting held in Washington DC, US, in October. The controversy, which dominated the World Congress of Cardiology, in Barcelona, Spain, the previous month, centres around concern about a possible increase in late stent thrombosis leading to death and myocardial infarction (MI) in patients receiving drug-eluting stents.
There are currently no comments for this article - leave a comment
You must be logged in to post a comment.
Not yet a member? Register now for free.
You need to be a member to print this page.
Sign up for free membership, or log in.
Find out more about our membership benefits
You need to be a member to download PDF's.
Sign up for free membership, or log in.
Find out more about our membership benefits